Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Degarelix
A GnRH antagonist approved for advanced prostate cancer — hormone suppression without the initial flare.
Cetrorelix
The other widely used GnRH antagonist in assisted reproduction protocols.
How far human research has progressed
Degarelix
Approved oncology medicineCetrorelix
Approved medicine in assisted reproductionClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Degarelix
Not separately assessed; see the full profile.Cetrorelix
Not separately assessed; see the full profile.Human research context
Degarelix
Approved oncology medicineCetrorelix
Approved medicine in assisted reproductionHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Degarelix
Cetrorelix
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Degarelix
Cetrorelix
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Degarelix
Cetrorelix
Regulatory status (legal position, not proof it works)
Degarelix
Named regulators: FDA (US)
FDA-approved (Firmagon) for treatment of advanced prostate cancer. Approval is specific to that oncology indication.
Cetrorelix
Named regulators: FDA (US)
FDA-approved (Cetrotide) for inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Indication-specific.
Common claims
Degarelix
- · Testosterone suppression in advanced prostate cancer without an initial surge
Cetrorelix
- · Prevents premature LH surges in controlled ovarian stimulation
How settled our evidence rating is
Degarelix
Cetrorelix
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Degarelix
Used to treat prostate cancer by suppressing androgen signalling — a therapeutic context, not a cancer-risk concern.Cetrorelix
No established human cancer signal within approved use.What this adds up to, in plain English
Degarelix
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Cetrorelix
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation